This information is intended for patients prescribed apixaban in UK only.
Apixaban patient information booklet
This booklet is for your information as you have been prescribed apixaban for the treatment of DVT and / or PE, or prevention of recurrent DVT and / or PE.
Apixaban (ELIQUIS) can also be used to treat other conditions:
- Stroke prevention in patients with non-valvular atrial fibrillation (NVAF)
- Prevention of venous thromboembolic events (VTE) following orthopaedic surgery
If you are unsure what you have been prescribed apixaban for, please check with your doctor as the information in this booklet may not be relevant to you.
It may be read in its electronic format (PDF) or it may be printed and read.
If you wish to print it, please ensure that:
- It is printed in its entirety. It is designed to be printed in its entirety, please do not attempt to print and use individual pages in isolation
- It is printed in colour
- It is printed in A4 size
- The pages are placed in the correct order as per the page numbering.
This booklet does not replace the patient information leaflet in your medication package which you should always read before you take your medicine. If you have any questions, please discuss with your doctor, nurse or pharmacist.
Please select the language of the Patient Information Booklet you would like to view below:
Patients prescribed apixaban
This section is intended for patients prescribed apixaban in the UK to provide information on this medicine, and its uses. It is not intended to replace in any way the opinion of a healthcare professional. For specific information about the pathology and/or detection, diagnosis, prognosis, administration and, where applicable, appropriate treatment for each specific case, please promptly consult a healthcare professional. The use of this website is subject to the legal notice, the privacy and cookie policy, the pharmacovigilance notice (if appropriate) and the applicable laws and regulations.
Report Side Effects
If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Side effects for this medicine should also be reported to
*Quality & Outcomes Framework prevalence data 2018-19; NHS Digital/Public Health Scotland/StatsWales/DH Northern Ireland ~ [undiagnosed] BHF analysis of PHE prevalence estimates (2019) and diagnosed data (QOF 2018/19)